Integrated PTSD and weight-management program for Veterans with obesity.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial compares HARPP, a manualized 16-session individually delivered program that combines VA MOVE! behavioral weight management, cognitive processing therapy (CPT), and medication review/management, to usual VA care. HARPP includes chart review for obesogenic medications, eligibility checks for anti-obesity medications, about 2–3 virtual visits with an obesity specialist, and coordinated care with Veterans' teams. The trial builds on a small pilot (n=7) that reported high satisfaction and promising weight loss and PTSD symptom reduction. The study also collects data on barriers and facilitators to implementing HARPP across VA if it proves effective.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Veteran adult
2. Current PTSD Diagnosis per the revised Clinician-Administered PTSD Scale for DSM-5 (CAPS-5-R)
3. Obesity: BMI of 30 kg/m2
4. Enrolled in VA Puget Sound primary care to ensure safety and facilitate HARPP's medication component
5. Willing to do intervention or control and assessments

Exclusion Criteria:

1. Not fluent in English, severe hearing loss, no phone access
2. Recent MOVE! or CPT participation (2 visits in past 2 months)
3. Had bariatric surgery in past 6 months or plans to receive it in next 12 months
4. At least 1 fill of AOM in the past 90 days
5. Current pregnancy
6. Any history of a bulimia diagnosis and/or meets criteria for bulimia
7. Cannot participate due to a) acute substance use, mental health, or medical exacerbation or b) at least moderate neurologic conditions, e.g., dementia
8. Current weight 600lbs or greater to accommodate study scale restrictions
9. Unable to complete a standing weight and height measurement to accommodate study scale restrictions

Where it's running

• VA Puget Sound Health Care System Seattle Division, Seattle, WA
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Katherine D Hoerster, PhD MPH BA — VA Puget Sound Health Care System Seattle Division, Seattle, WA
• Study coordinator: Michelle L Upham, MSW
• Email: michelle.upham@va.gov
• Phone: (206) 277-1961

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.